Limits...
Efficacy of adalimumab across subgroups of patients with moderate-to-severe chronic plaque psoriasis of the hands and/or feet: post hoc analysis of REACH.

Poulin Y, Crowley JJ, Langley RG, Unnebrink K, Goldblum OM, Valdecantos WC - J Eur Acad Dermatol Venereol (2013)

Bottom Line: In adalimumab-treated patients, greater percentages of NAPSI 50 Responders vs.Non-responders achieved the primary endpoint, and had greater improvements in erythema, scaling, induration and fissuring, Dermatology Life Quality Index, and pain scores.Marked improvement in nail psoriasis among adalimumab-treated patients correlated with significant improvements in skin disease and patient-reported outcomes.

View Article: PubMed Central - PubMed

Affiliation: Centre Dermatologique du Québec Métropolitain, Québec, Canada.

Show MeSH

Related in: MedlinePlus

Nail psoriasis improvement in one patient. Images from a white, 63-year-old male patient, illustrate improvement in the patient’s nail psoriasis (left hand, digit 4) from baseline to week 16 following adalimumab treatment. This patient was previously treated with corticosteroids and infliximab, but did not achieve response with infliximab. Nail Psoriasis Severity Index target fingernail scores range from 0 to 8.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4229025&req=5

fig04: Nail psoriasis improvement in one patient. Images from a white, 63-year-old male patient, illustrate improvement in the patient’s nail psoriasis (left hand, digit 4) from baseline to week 16 following adalimumab treatment. This patient was previously treated with corticosteroids and infliximab, but did not achieve response with infliximab. Nail Psoriasis Severity Index target fingernail scores range from 0 to 8.

Mentions: Among patients with nail psoriasis at baseline, a greater percentage of adalimumab-treated patients (56.5%) compared with placebo-treated patients (12.5%) achieved NAPSI 50 at week 16 (Fig. 3a). Improvement in nail psoriasis at week 16 following treatment with adalimumab is shown in Fig. 4. Further evaluation showed that in adalimumab-treated patients, a greater percentage of NAPSI 50 Responders (61.5%) achieved an hfPGA score of clear or almost clear compared with NAPSI 50 Non-Responders (20.0%) (Fig. 3b). In addition, NAPSI 50 Responders among adalimumab-treated patients demonstrated greater mean percent improvements in ESIF scores (77.6%) and DLQI scores (74.0%) compared with NAPSI 50 Non-Responders (37.2% and 53.6% respectively) (Fig. 3c). Finally, NAPSI 50 Responders experienced a greater mean reduction in pain VAS score (86.1%) than NAPSI 50 Non-Responders (1.4%) among patients treated with adalimumab (Fig. 3c).


Efficacy of adalimumab across subgroups of patients with moderate-to-severe chronic plaque psoriasis of the hands and/or feet: post hoc analysis of REACH.

Poulin Y, Crowley JJ, Langley RG, Unnebrink K, Goldblum OM, Valdecantos WC - J Eur Acad Dermatol Venereol (2013)

Nail psoriasis improvement in one patient. Images from a white, 63-year-old male patient, illustrate improvement in the patient’s nail psoriasis (left hand, digit 4) from baseline to week 16 following adalimumab treatment. This patient was previously treated with corticosteroids and infliximab, but did not achieve response with infliximab. Nail Psoriasis Severity Index target fingernail scores range from 0 to 8.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4229025&req=5

fig04: Nail psoriasis improvement in one patient. Images from a white, 63-year-old male patient, illustrate improvement in the patient’s nail psoriasis (left hand, digit 4) from baseline to week 16 following adalimumab treatment. This patient was previously treated with corticosteroids and infliximab, but did not achieve response with infliximab. Nail Psoriasis Severity Index target fingernail scores range from 0 to 8.
Mentions: Among patients with nail psoriasis at baseline, a greater percentage of adalimumab-treated patients (56.5%) compared with placebo-treated patients (12.5%) achieved NAPSI 50 at week 16 (Fig. 3a). Improvement in nail psoriasis at week 16 following treatment with adalimumab is shown in Fig. 4. Further evaluation showed that in adalimumab-treated patients, a greater percentage of NAPSI 50 Responders (61.5%) achieved an hfPGA score of clear or almost clear compared with NAPSI 50 Non-Responders (20.0%) (Fig. 3b). In addition, NAPSI 50 Responders among adalimumab-treated patients demonstrated greater mean percent improvements in ESIF scores (77.6%) and DLQI scores (74.0%) compared with NAPSI 50 Non-Responders (37.2% and 53.6% respectively) (Fig. 3c). Finally, NAPSI 50 Responders experienced a greater mean reduction in pain VAS score (86.1%) than NAPSI 50 Non-Responders (1.4%) among patients treated with adalimumab (Fig. 3c).

Bottom Line: In adalimumab-treated patients, greater percentages of NAPSI 50 Responders vs.Non-responders achieved the primary endpoint, and had greater improvements in erythema, scaling, induration and fissuring, Dermatology Life Quality Index, and pain scores.Marked improvement in nail psoriasis among adalimumab-treated patients correlated with significant improvements in skin disease and patient-reported outcomes.

View Article: PubMed Central - PubMed

Affiliation: Centre Dermatologique du Québec Métropolitain, Québec, Canada.

Show MeSH
Related in: MedlinePlus